Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced that it has commenced an underwritten public offering of $500,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis.
July 6, 2020
· 5 min read